Posted inHematology-Oncology news
CPX-351 versus CLAG-M in Medically Unfit Adults with AML: A Phase 2 Randomized Study Evaluating Survival and Response Outcomes
This phase 2 trial compares CPX-351 with CLAG-M chemotherapy in medically unfit adults with AML, finding CLAG-M achieves better 3-month survival and response rates, especially in patients with proliferative disease, suggesting intensive therapy benefits select subgroups.